43 results about "Anticholinergic Drugs" patented technology

Administering to a patient an anticholinergic medication comprising scopolamine and hydroxyzine can alleviate the symptoms of nicotine withdrawal. Used in conjunction with pre- and post-administration counseling, smoking cessation rates may be significantly improved.

The invention provides a method for the treatment of H4R modulated diseases and / or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.

New stable compositions comprising the combination of a topically active vasoconstrictor and a topically active anticholinergic drug are disclosed. Preferably, the composition comprises ipratropium or a salt thereof in combination with xylometazoline hydrochloride and a salt thereof. Upon topically administering such compositions to a nasal mucosa in individuals suffering from the common cold the symptoms of rhinorrhea are significantly reduced.

The invention discloses anagrobacterium radiobacter, a quininone reductase expressed thereby and a gene thereof, recombinant expression plasmid containing the gene, recombinant expression vector containing the gene, a recombinase of quininone, a preparation method of the recombinase , and application of the recombinase to asymmetric reduction of 3-quininone as a catalyst for preparation of (R)-3-quinuclidinol. Compared with other preparation methods for (R)-3-quinuclidinol, the (R)-3-quinuclidinol prepared by employing the quininone reductase provided by the invention is not only high in product concentration, but also good in optical purity; the reaction condition is mild, the operation is convenient, and the preparation is easy to amplify; and therefore the application of the quininone reductase to asymmetric synthesis of (R)-3-quinuclidinol has extremely good industrial application prospect in the production of intermediates of anticholinergic drugs.

An aerosol solution formulation comprising:(a) a salt of formula 1wherein X− is an anion(b) an HFC propellant;(c) a cosolvent; and(d) an inorganic or an organic acid, wherein the concentration of the acid is in a range that corresponds with a pH range of 2.5 to 5.5 in aqueous solution.

The invention provides a method for the treatment of H4R modulated diseases and / or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.

The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse reactions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X− is an anion; the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and / or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

Pharmaceutical formulation in the form of inhalable dry powder comprising particles of a pharmaceutically acceptable salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane as active ingredient, and particles of a carrier made of a physiologically acceptable pharmacologically-inert material are effective for the prevention and / or treatment of a respiratory disease such as asthma and COPD.

The invention discloses a medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances. The medicament is prepared from the following components by weight percent: 2-95% of antipsychotics, 0.001-5% of alpha2 adrenergic agonists, 0-5% of anticholinergic agent, 0-80% of nonopioid analgesic, and 0-10% of benzodiazepine. The pharmaceutical composition disclosed by the invention achieves an ideal effect when the symptoms of a sufferer abusing stimulants such as benzedrine, or abusing the opiates substances in a merging manner are treated; the withdrawal symptom can be rapidly and obviously controlled; the detoxification recovery rate can be up to over 90%.

The invention relates to an anticholinergic pharmaceutical composition. Specifically, the invention relates to a medicament capable of being used in pharmacy, wherein the,medicament comprises a compound expressed by the following formula. The invention further provides a preparation of the medicament, and the medicament and the preparation are used as an anticholinergic medicament and can be clinically used for anesthesia, peptic ulcer, salivation, etc. The raw material medicament or preparation has the function of inhibiting gastric secretion and regulating gastrointestinal peristalsis; the raw material medicament or preparation has relatively strong salivary secretion resistance than atropine while having no central anticholinergic activity. The anticholinergic pharmaceutical composition is generally used for clinically treating such symptoms as gastric and duodenal ulcer, chronic gastritis and excessive secretion of gastric acid.

The invention provides a pharmaceutical composition preparation. The pharmaceutical composition preparation comprises an anticholinergic drug tiotropium or a hydrate thereof, a beta 2-receptor agonistarformoterol or a salt thereof, and an inhaled glucocorticoid fluticasone or an ester derivative thereof; tiotropium bromide acts on a muscarinic receptor on bronchial smooth muscles, the cholinergiceffect of acetylcholine released by the tail ends of parasympathetic nerves can be inhibited, and muscular tension is blocked; the arformoterol acts on a beta 2-receptor on an airway smooth muscle cell membrane, so that the release of degranulation and media of mast cells and basophils is reduced, the permeability of capillaries is reduced, and swinging of airway epithelial cilia is increased; the fluticasone is an effective anti-inflammatory drug, and when the three drugs are combined for use, the three mechanisms jointly exert the bronchus relaxing effect and the anti-inflammatory effect; the application range of the triple therapy is wider on the important clinical indexes of reducing acute exacerbation of patients suffering from chronic obstructive pulmonary disease, reducing total-cause mortality rate, improving the lung function of the patients suffering from chronic obstructive pulmonary disease, improving the living quality and the like.

The invention provides anticholinergic agents that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the anticholinergic agent not attached to the water-soluble oligomer.

The invention provides application of a radix physochlainae extract in preparation of drugs for preventing and treating myopia. Effective compositions such as anisodamine, scopolamine and scopoletin in the radix physochlainae extract are obtained through tests, the purpose of preventing and treating myopia can be achieved, and the defect that clinical application cannot be achieved due to potential side effects caused by long-term single use of anticholinergic drugs can be effectively overcome. The radix physochlainae extract has a remarkable treatment effect on myopia, is high in safety, andis expected to be popularized and applied clinically. Experiments prove that the radix physochlainae extract can be used for improving myopia by regulating scleral fibrous layers and retinal pigment cells, influencing expression of matrix metalloproteinase 2, matrix metalloproteinase inhibitor 2 and the like, regulating spasm of ciliary muscles and the like. The invention also provides a composition. The composition comprises effective components of the radix physochlainae extract; and the composition provides a new way for preventing and treating myopia.

The invention relates to a drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome, which comprises the following components in percent by weight: 2-95 percent of antipsychotics, 0.001-5 percent of a2 adrenergic receptor agonist, 0-5 percent of anticholinergic drug, 0-80 percent of non-opiates pain easing agent and 0-10 percent of benzodiazepines drugs. When used for treating symptoms occurring in patients abusing exhilarants of Benzedrine and the like or integrally abusing opioid, the drug achieves better effect, can rapidly and remarkably control abstinence syndrome, and has detoxification cure rate reaching over 90 percent.

A treatment regimen for rhinitis with rhinorrhea includes a daytime dosage unit containing medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea, and a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent. A pharmaceutical package for treating rhinitis with rhinorrhea includes a daytime dosage unit containing a medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea, a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent, indicia to distinguish between the daytime dosage unit and the nighttime dosage unit, instructions for coordinating the daytime dosage unit and the nighttime dosage unit as a treatment regimen for treating rhinitis with rhinorrhea, and a unifying container for housing the daytime dosage unit, the nighttime dosage unit, the indicia, and the instructions.

The invention discloses a vilanterol trifluoromethanesulfonate-containing pharmaceutical preparation, which comprises the following main active ingredients: long-acting beta2 receptor agonist vilanterol trifluoromethanesulfonate, glucocorticoid drug fluticasone furoate and long-acting anticholinergic drug aclidinium bromide, or physiologically acceptable salts of the fluticasone furoate and aclidinium bromide, thus composing a compound preparation. The vilanterol trifluoromethanesulfonate has the effect of continuously dilating blood vessels for 24 hours; the fluticasone furoate is fast-acting potent glucocorticoid, and the duration time of the drug is longer than that of other glucocorticoids; the aclidinium bromide is long-acting cholinergic receptor antagonist, and combines with beta2 receptor agonist so as to play roles of synergism and reduction of adverse drug reaction. The vilanterol trifluoromethanesulfonate, the fluticasone furoate and the aclidinium bromide are combined for use to prepare an inhalable compound preparation which can be taken once daily due to 24-hour acting. The vilanterol trifluoromethanesulfonate-containing pharmaceutical preparation can enhance the curative effect, solves the compliance problem of patients with coexisting chronic obstructive pulmonary disease and asthma, thus being appreciable in application prospects.

A method is described for treatment of nicotine dependency and cessation or reduction of tobacco use in humans which combines pharmacotherapy designed to ameliorate the initial withdrawal symptoms followed by behavioral modification intended to minimize the relapse rate. Pharmacotherapy consists of the use of anticholinergic agents, which facilitate a smooth withdrawal from nicotine. A composition is described comprising scopolamine, glycopyrrolate and benztropine which is injected parenterally. In addition the individuals participate in weekly counseling sessions for at least 4 weeks after treatment.

Pharmaceutical formulations suitable to be administered by pressurised metered dose inhalers (pMDIs) comprising a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane are effective for the prevention and / or treatment of an obstructive airways disease.

The invention relates to cholinolytic drug glycopyrronium bromide and a composition, in particular to a pharmaceutical drug and a preparation thereof. The drug contains a compound with the formula shown in the specification and an enantiomer of the compound. Serving as an anticholinergic drug, the drug and the preparation can be clinically applied to anesthesia, peptic ulcers, salivation and the like. The bulk drug or the preparation has the effects of restraining gastric secretion and regulating gastrointestinal peristalsis, has a stronger salivation resisting effect than atropine, but has no central anticholinergic activity. Generally, the drug or the preparation is clinically applied to gastric and duodenal ulcers, chronic gastritis, excessive gastric acid secretion and the like.

The invention relates to a medicine tiotropium bromide spray for treating respiratory diseases, especially asthma, chronic obstructive pneumonia, trachitis and the like. An inhalable surfactant enables the spray particle size, spray time and spray speed of the composition to be more suitable by adjusting the surface tension of a spray pharmaceutical composition of M1, M2 and / or M3 receptor anticholinergic drugs without propellants.

A inhaler for an inhalation formulation, comprising a canister containing a pharmaceutical composition under pressure; a metering valve for measuring a metered dose of the composition from the canister for administration to a patient in need thereof; and an actuator for actuating discharge of the metered dose to the patient; wherein the actuator includes a discharge orifice having a diameter in the range 0.2 to 0.4 mm; and wherein the pharmaceutical composition comprises an anticholinergic agent and a pharmaceutically acceptable propellant.

Pharmaceutical compositions are provided including therapeutically effective amounts of an α1 adrenergic receptor antagonist, together with one or more of (1) a mu (or opioid receptor subtype) antagonist or agonist, (2) a vasopressor, (3) an anticholinergic agent and / or cholinergic agents. (4) a combined alpha-1 adrenergic antagonist and anticholinergic (e.g. droperidol), (5) a paralytic or muscle relaxant, (6) a respiratory accelerant, (7) a GABA complex antagonist, (8) an anti-seizure / membrane stabilizer agent, (9) an α1 adrenergic receptor agonist, and / or (10) an α2 adrenergic receptor agonist; and a pharmaceutically acceptable carrier. Also provided are methods of preventing or reversing effects in a subject (including muscle and chest wall rigidity, laryngospasm, WCS, and / or respiratory depression) arising from intentional or accidental opioid or opiate exposure, involving administering to the subject such a pharmaceutical composition. Methods of providing analgesia with a modified side effect profile to reduce risk of WCS or respiratory effects are also provided.

The present invention relates to a bromo-1-cyclopropylmethyl-3-(2-phenyl-2-cyclopentyl-2-hydroxyoxyethyl) quinuclidane medicine compound, its preparation method and application of said medicine compound in preparation of anticholinergic and medicine for curing respiratory diseases. The invented medicine compound can selectively act on receptor M1 and receptor M3 and does not act on receptor M2, and is not easy to permeate through blood-brain barrier, so that it can reduce pharmacy frequency of patient and can reduce therapeutic cost.

The invention provides a combined drug for treating psoriasis. The combined drug includes an anticholinergic drug and a sedative drug used in combination. According to the combined drug provided by the invention, the anticholinergic drug and the sedative drug are used according to a specific ratio, so that the treatment effect can be effectively enhanced, onset of psoriasis patients can be delayed, and the degree of skin damage to scalps, nails, hands and feet can be improved; the combined drug provided by the invention has little or no side effects and high safety; and at the same time, the combined drug provided by the invention can effectively treat the psoriasis, the effect is better than that of an anticholinergic drug scopolamine alone, so that results indicate that the drug providedby the invention has a synergistic effect when used in combination according to the specific ratio, and has a good clinical application prospect.

A method is disclosed for the management of dry mouth associated with the administration of an anticholinergic drug to a patient. Also, a composition and a device are disclosed comprising an anticholinergic drug administered for anticholinergic therapy.

The invention discloses a method capable of simultaneously detecting various anticholinergic drugs. The anticholinergic drugs at least comprise atropine, anisodamine, scopolamine methobromide and scopolamine butylbromide; the detection method adopts CE-ESI-MS (Capillary Electrophoresis-Electrospray mass spectrometry), in the detection process, the separation voltage, the buffer solution, the sheath fluid type and the sheath fluid flow velocity parameter are set as follows: the separation voltage is 10-21 kV; the buffer solution is an ammonium acetate buffer solution with a pH value of 9.4, thesheath fluid type is an isopropanol-aqueous solution added with acetic acid, and the sheath fluid flow velocity is 2.0-4.0 [mu]L / min. According to the scheme, high-efficiency and rapid separation andanalysis can be realized by adopting a CE-MS coupling technique, thereby reducing the consumption of an organic solvent; compared with an HPLC-MS (High Performance Liquid Chromatography-Mass Spectrometry) technique in the prior art, the method has the advantages of being small in sample amount and the like; and the scheme in the invention is combined with high-efficiency separation of capillary electrophoresis and an accurate qualitative function of mass spectra, so that the detection result is more accurate.

The invention relates to the field of radiooncology. The methods according to the invention comprise the use of botulinum toxins and anticholinergic agents to prevent glands from radiation damage and side effects due to radioactive ligands. The method according to the invention further comprises the use of botulinum toxins to prevent the glands from radiation damage, wherein the radiation damage is caused by radioactive ligands. By using the method according to the invention, the invention can provide effective protection of the glands to avoid radiation damage.

The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a selective alpha-adrenergic receptor agonist or an anticholinergic agentor a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein the selective alpha-adrenergic receptor agonist or anticholinergic agent is selected from the group consisting of pilocarpine, brimonidine and oxymetazoline, or a pharmaceutically acceptable salt or a stereoisomer thereof, and their uses in the treatment or alleviation of xerostomia, dermal diseases and eye disorders.

The invention provides a combined drug for treating chronic, intractable or primary insomnia. The combined drug comprises an anticholinergic drug and a sedative drug which are combined for use. According to the invention, the anticholinergic drug and the sedative drug are used according to a specific ratio, so the treatment effect can be effectively enhanced, and the morbidity of chronic, intractable or primary insomnia patients is delayed. The combined drug provided by the invention is small in side effects or free of side effects and high in safety. Meanwhile, the combined drug provided by the invention can effectively treat the chronic, intractable or primary insomnia; the effect of the combine drug is superior to the effect of dexmedetomidine for independent use; thus, the combined drug is indicated to have a synergistic effect in combined use in a specific ratio and have good clinical application prospect.